All In Biotech

Drug Trial Radar · NCT01564537

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Mar 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 722 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

722

Actual

Start

Aug 1, 2012

Primary completion

Oct 1, 2014

Study completion Feb 8, 2022

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Mar 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM).

Conditions

  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma

Interventions

  • IxazomibDrug

    Ixazomib capsules

  • LenalidomideDrug

    Lenalidomide capsules

  • DexamethasoneDrug

    Dexamethasone tablets

  • PlaceboDrug

    Ixazomib placebo-matching capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)Time frame: From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months)

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Arkansas Medical Sciences

    Little Rock, Arkansas

  • Pacific Cancer Medical Center Inc

    Anaheim, California

  • West Contra Costa Healthcare District

    Berkeley, California

  • University of Florida

    Gainesville, Florida

  • Cancer & Blood Disease Center

    Lecanto, Florida

  • Northwest Georgia Oncology Center

    Marietta, Georgia

  • John H. Stroger, Jr. Hospital of Cook County

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Columbia University Medical Center

    New York, New York

  • Blood and Cancer Clinic

    Fayetteville, North Carolina

  • Scranton Hematology Oncology

    Scranton, Pennsylvania

  • MUSC Hollings Cancer Center

    Charleston, South Carolina

  • Fred Hutchinson Cancer Research

    Seattle, Washington

  • West Virginia University Hospitals and Clinic

    Morgantown, West Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

  • Saint John Regional Hospital

    Saint John, New Brunswick, Canada

  • CHUM Notre-Dame Hospital

    Montreal, Quebec, Canada

  • MUHC Glen Site Cedars Cancer Centre

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.